As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch
Joel Wayment, Cardinal Health 3PL Services
Advertisement
Articles by Joel Wayment, Cardinal Health 3PL Services
Advertisement
Latest Updated Articles
3PL Outsourcing Models: Which is best for your business?Published: November 5th 2019 | Updated:
CAR-T Therapies: Three Supply Chain ConsiderationsPublished: February 10th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Great Repricing: How Pharma Must Evolve for Three Diverging Payer Economies
2
Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap
3
Trade & Channel Strategies 2025: Inside Pharma’s Turning Point
4
Working with the Middle
5
